NASDAQ •
Healthcare •
Diagnostics & Research •
Quote as of 06/26/2026 16:00
Company Profile
IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,401.52 mln
Float49.32 mln
Earnings Date07/30/2026
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-3.57
Highly reliable
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.08
Debt-free
ROE
-2.51
Negative
Dividend Yield
0.00%
No dividend
Business Description
CareDx helps transplant patients achieve better health outcomes by providing a range of testing and monitoring tools used before, during, and after organ transplantation. Its products include blood tests that detect signs of organ rejection, software platforms that help medical teams manage patient care, and laboratory solutions that support tissue matching between donors and recipients. The company serves patients who have received kidney, heart, and lung transplants, as well as those who have undergone stem cell procedures. Founded in 1998 and based in Brisbane, California, CareDx operates across the United States and in international markets.
